Common Side Effects in Kids on Cosentyx
Cosentyx (secukinumab), approved for kids aged 6 and older with moderate to severe plaque psoriasis or enthesitis-related arthritis, carries side effects similar to adults but with pediatric-specific data from trials. Upper respiratory infections top the list, affecting about 20-30% of children in studies, including nasopharyngitis and pharyngitis. Diarrhea occurs in around 10-15%, injection-site reactions in 5-10%, and oral herpes in up to 5%. These are mostly mild to moderate and lead to discontinuation in under 2% of cases.[1][2]
Serious Risks and Infections
Serious infections happen in roughly 1-2% of pediatric patients, lower than adult rates but still notable—think tuberculosis reactivation or invasive fungal infections. The drug suppresses IL-17A, raising infection risk, so screening for latent TB is required before starting. Inflammatory bowel disease (IBD) flares or new onset affect about 1%, with Crohn's-like symptoms in rare cases. No increased malignancy risk shows in pediatric trials up to 52 weeks, but long-term data is limited.[1][3]
How Side Effects Differ from Adults
Pediatric trials (e.g., CAPS and JUNIPERA studies) report lower overall rates of severe events compared to adults—serious adverse events at 5.4% vs. 6-8% in adults. Kids experience more eczema and urticaria (up to 4%), possibly due to developing immune systems. Growth or bone effects aren't flagged as issues in available data.[2][4]
Monitoring and When to Worry
Doctors track for infections, IBD symptoms (abdominal pain, bloody stools), and hypersensitivity. Live vaccines are off-limits during treatment. In trials, 98% of kids continued without stopping for side effects. Report fever, persistent diarrhea, or skin changes immediately.[1][3]
Long-Term Data and Rare Events
Over 52 weeks, no new pediatric-specific risks emerge beyond adult patterns. Post-marketing reports include anaphylaxis (rare) and neutropenia. Ongoing studies monitor beyond age 6; use in younger kids lacks approval.[2]
[1]: Cosentyx Prescribing Information (Novartis, 2023)
[2]: FDA Label for Pediatric Psoriasis (2020)
[3]: CAPS Study (NEJM, 2020)
[4]: JUNIPERA Trial (Lancet, 2022)